Stereotactic Body Radiotherapy for Spine Tumors
Completed · Not applicable
Conditions studied: Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma, Meningioma, Schwannoma, Neurofibroma, Paragangliomas, Arteriovenous Malformations
In brief
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
Key facts
- Study ID
- NCT01347307
- Run by
- Mercy Research
- People needed
- 38
- Starts
- 2008-09-01
- Expected to finish
- 2017-09-01
- Last updated by the study team
- 2020-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Lesion involving > 3 adjacent vertebral levels
- Overt spinal instability
- Neurologic deficit due to bony fragments/bony compression of neural structures
- Prior radiotherapy at the involved level(s) within 3 months of radiosurgery, more than one prior course of radiotherapy at the involved level(s), or more than 45 Gy previous radiation exposure at the involved level(s)
- Rapidly progressive spinal cord compromise or neurological deficit
- Paralysis, or otherwise compromised motor function due to radiographically confirmed cord compression
- Patient unable to undergo an MRI
- Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females
- Patients with psychiatric or addictive disorder that would preclude obtaining informed consent
Where it is running
- Mercy Medical Center, St. Louis — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.